CR20190426A - Inmunoconjugados - Google Patents

Inmunoconjugados

Info

Publication number
CR20190426A
CR20190426A CR20190426A CR20190426A CR20190426A CR 20190426 A CR20190426 A CR 20190426A CR 20190426 A CR20190426 A CR 20190426A CR 20190426 A CR20190426 A CR 20190426A CR 20190426 A CR20190426 A CR 20190426A
Authority
CR
Costa Rica
Prior art keywords
immunoconjugates
polynucleotide molecules
relates
mutant
polypeptide
Prior art date
Application number
CR20190426A
Other languages
English (en)
Inventor
Inja Waldhauer
Deak Laura Codarri
Laura Lauener
Christian Klein
Pablo Umaña
Stefan Seeber
Valeria G Nicolini
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20190426A publication Critical patent/CR20190426A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere de manera general a inmunoconjugados, en particular inmunoconjugados que comprenden un polipéptido interleuquina-2 mutante y un anticuerpo que se une a PD-1. Además, la invención se refiere a moléculas de polinucleótido codificantes de los inmunoconjugados y a vectores y células huésped que comprenden dichas moléculas de polinucleótido. La invención se refiere además a métodos para producir los polipéptidos mutantes, a composiciones farmacéuticas que los comprenden y a usos de los mismos.
CR20190426A 2017-04-03 2018-03-29 Inmunoconjugados CR20190426A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164533 2017-04-03
PCT/EP2018/058034 WO2018184964A1 (en) 2017-04-03 2018-03-29 Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15

Publications (1)

Publication Number Publication Date
CR20190426A true CR20190426A (es) 2019-11-01

Family

ID=58488892

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190426A CR20190426A (es) 2017-04-03 2018-03-29 Inmunoconjugados

Country Status (30)

Country Link
US (3) US11413331B2 (es)
EP (2) EP3606946B1 (es)
JP (3) JP7426825B2 (es)
KR (2) KR20190121816A (es)
CN (2) CN110392692B (es)
AR (2) AR111400A1 (es)
AU (1) AU2018247765B2 (es)
CL (1) CL2019002346A1 (es)
CO (1) CO2019009354A2 (es)
CR (1) CR20190426A (es)
DK (1) DK3606946T3 (es)
ES (1) ES2928718T3 (es)
HR (1) HRP20221254T1 (es)
HU (1) HUE059885T2 (es)
IL (1) IL269395B2 (es)
LT (1) LT3606946T (es)
MA (1) MA49033B1 (es)
MX (2) MX2019011770A (es)
MY (1) MY201482A (es)
PE (1) PE20191494A1 (es)
PH (1) PH12019502273A1 (es)
PL (1) PL3606946T3 (es)
PT (1) PT3606946T (es)
RS (1) RS63663B1 (es)
RU (1) RU2761377C2 (es)
SG (1) SG11201909205YA (es)
TW (1) TWI800506B (es)
UA (1) UA125700C2 (es)
WO (1) WO2018184964A1 (es)
ZA (1) ZA201905517B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100506T1 (it) 2015-10-02 2021-11-12 Hoffmann La Roche Anticorpi bispecifici specifici per pd1 e tim3
AU2017339856B2 (en) * 2016-10-06 2024-09-05 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
CN107082812B (zh) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
KR20190121816A (ko) 2017-04-03 2019-10-28 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
PL3606955T3 (pl) 2017-04-05 2025-02-24 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
ES2910969T3 (es) 2017-08-03 2022-05-17 Amgen Inc Muteínas de interleucina-21 y métodos de tratamiento
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
CA3086486A1 (en) 2018-09-17 2020-03-26 Gi Innovation, Inc. Fusion protein comprising il-2 protein and cd80 protein, and use thereof
TWI791894B (zh) 2018-09-21 2023-02-11 大陸商信達生物製藥（蘇州）有限公司 新型白介素２及其用途
CN113166272B (zh) * 2018-10-29 2024-07-23 北京强新生物科技有限公司 新型合理设计的蛋白质组合物
CN113573782B (zh) * 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
EP3898677A1 (en) * 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
WO2020247843A2 (en) * 2019-06-05 2020-12-10 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
WO2020259536A1 (zh) * 2019-06-24 2020-12-30 南京金斯瑞生物科技有限公司 单克隆抗体-细胞因子融合蛋白二聚体及其应用
CN116574183A (zh) * 2019-08-22 2023-08-11 盛禾(中国)生物制药有限公司 多功能抗体、其制备及其用途
CN112679615B (zh) * 2019-10-17 2023-09-22 瑞阳(苏州)生物科技有限公司 一种融合蛋白
US20220380487A1 (en) * 2019-10-24 2022-12-01 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
EP4063490A4 (en) * 2019-11-20 2023-08-23 GI Cell, Inc. COMPOSITION FOR THE CULTURE OF REGULATORY T LYMPHOCYTES AND THEIR USE
KR102351020B1 (ko) 2019-11-20 2022-01-14 주식회사 지아이셀 자연살해세포 배양용 조성물 및 이를 이용한 자연살해세포 제조방법
IL292934A (en) * 2019-11-20 2022-07-01 Gi Cell Inc Composition of medium for t-cell culture and method for culture of t-cells using the same composition of medium
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
JP7488337B2 (ja) * 2019-11-27 2024-05-21 ジーアイ・セル・インコーポレイテッド Ｉｌ－２タンパク質及びｃｄ８０タンパク質を含む融合タンパク質及びｎｋ細胞を含む抗癌治療用組成物
WO2021119516A1 (en) * 2019-12-13 2021-06-17 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
CA3159555A1 (en) * 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
TW202136317A (zh) 2019-12-20 2021-10-01 美商再生元醫藥公司 新穎之ｉｌ２促效劑及其使用方法（二）
EP4076388A1 (en) * 2019-12-20 2022-10-26 Ares Trading S.A. Igg:tgfbetarii fusion protein composition
EP4087866A1 (en) * 2020-01-09 2022-11-16 F. Hoffmann-La Roche AG New 4-1bbl trimer-containing antigen binding molecules
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
KR102559355B1 (ko) * 2020-01-31 2023-07-25 주식회사 제넥신 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
CA3168607A1 (en) 2020-02-13 2021-08-19 F. Hoffmann-La Roche Ag Method for determining the loading state of an aav particle by nuclear magnetic resonance relaxometry
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN115485028A (zh) * 2020-04-15 2022-12-16 豪夫迈·罗氏有限公司 免疫缀合物
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
US20230181712A1 (en) 2020-05-11 2023-06-15 Hoffmann-La Roche Inc. Combination therapy with modified pbmcs and an immunoconjugate
JP2023526282A (ja) 2020-05-13 2023-06-21 ボナム セラピューティクス，インク． タンパク質複合体の組成物及びその使用方法
CN113667004A (zh) * 2020-05-14 2021-11-19 上海盖浦生物科技有限公司 一种白介素2突变体
US20230257438A1 (en) * 2020-06-30 2023-08-17 Gi Innovation, Inc. Fusion protein comprising anti-lag-3 antibody and il-2, and use thereof
JP2022045530A (ja) * 2020-09-09 2022-03-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－１標的化ｉｌ－２変異体免疫サイトカインとヒトｐｄ－ｌ１に対する抗体との併用療法
US11865082B2 (en) 2020-09-09 2024-01-09 Hoffmann-La Roche Inc. Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
EP4232071A4 (en) * 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
WO2022098954A1 (en) 2020-11-06 2022-05-12 Nektar Therapeutics Tlr agonist compounds and related cancer immunotherapy methods
TW202235431A (zh) 2020-11-25 2022-09-16 美商艾希利歐發展股份有限公司 腫瘤特異性可裂解連接子
CN116635403A (zh) * 2020-12-04 2023-08-22 豪夫迈·罗氏有限公司 pH依赖性突变型白细胞介素-2多肽
WO2022125694A1 (en) * 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
TW202241937A (zh) 2020-12-22 2022-11-01 荷蘭商新基因治療公司 用於追踪基因工程細胞的肽標記
CN114712495B (zh) * 2021-01-06 2024-08-20 盛禾(中国)生物制药有限公司 一种多功能抗体的组合物
WO2022148853A1 (en) * 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
EP4304724A1 (en) * 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
WO2022189377A1 (en) 2021-03-09 2022-09-15 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
CN117157312A (zh) 2021-03-30 2023-12-01 豪夫迈·罗氏有限公司 蛋白酶活化的多肽
CA3213917A1 (en) 2021-04-09 2022-10-13 Nicolas Poirier New scaffold for bifunctional molecules with improved properties
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
MX2023015444A (es) 2021-06-23 2024-04-29 Cytune Pharma Inmunocitocinas a base de interleucina-15.
BR112023027305A2 (pt) 2021-06-23 2024-03-12 Cytune Pharma Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
US20230303649A1 (en) 2021-07-09 2023-09-28 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
CN118119635A (zh) * 2021-09-22 2024-05-31 信达生物制药(苏州)有限公司 白介素2突变体以及其融合蛋白
EP4405487A4 (en) * 2021-09-26 2025-12-03 Wuxi Biologics Ireland Ltd IL-2 VARIANTS AND THEIR FUSING PROTEINS
EP4433097A1 (en) * 2021-11-17 2024-09-25 F. Hoffmann-La Roche AG Compositions of protein complexes and methods of use thereof
TWI857396B (zh) * 2021-11-18 2024-10-01 大陸商山東先聲生物製藥有限公司 Il-15突變體融合蛋白藥物組合物
CN116554344A (zh) * 2022-01-30 2023-08-08 中国科学院生物物理研究所 一种pd1抗体与白介素2融合的双功能分子
CN118510815A (zh) * 2022-02-11 2024-08-16 江苏恒瑞医药股份有限公司 免疫缀合物及其用途
EP4482531A1 (en) 2022-02-23 2025-01-01 Bright Peak Therapeutics AG Immune antigen specific il-18 immunocytokines and uses thereof
EP4514846A1 (en) * 2022-04-26 2025-03-05 Novartis AG Multispecific antibodies targeting il-13 and il-18
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
CN119790064A (zh) * 2022-08-23 2025-04-08 马斯得生物有限公司 Il2变体和包括该il2变体的蛋白复合体
JP2025534285A (ja) 2022-09-29 2025-10-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ポリペプチド
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
EP4491631A1 (en) 2023-07-13 2025-01-15 Anaveon AG Anti-pd-1 antibody binding domain and immunoconjugate
WO2024133825A1 (en) 2022-12-22 2024-06-27 Anaveon AG Anti-pd-1 antibody antigen-binding domain and immunoconjugate
EP4431525A1 (en) 2023-03-16 2024-09-18 Anaveon AG Il-2 fusion protein
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白
AU2024209384A1 (en) 2023-01-20 2025-06-26 F. Hoffmann-La Roche Ag Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
CN120584138A (zh) 2023-02-06 2025-09-02 豪夫迈·罗氏有限公司 组合疗法及其用途
CN118725136A (zh) * 2023-03-21 2024-10-01 上海赛金生物医药有限公司 抗pd-1/抗tigit双特异性抗体与il-2的融合蛋白及应用
WO2024193670A1 (zh) * 2023-03-21 2024-09-26 弗维塔生物制药（新加坡）有限公司 抗pd-1与突变il-2免疫缀合物制剂
WO2024199458A1 (en) * 2023-03-29 2024-10-03 Wuxi Biologics (Shanghai) Co., Ltd. Il-2 variants with improved stability and compositions thereof
TW202509065A (zh) 2023-05-16 2025-03-01 瑞士商赫孚孟拉羅股份公司 經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
WO2025036449A1 (zh) * 2023-08-16 2025-02-20 上海迈晋生物医药科技有限公司 一种包含免疫缀合物的药物组合物及其用途
WO2025137093A1 (en) 2023-12-19 2025-06-26 Cephalon Llc Uses for attenuated il-2 immunoconjugates
WO2025202147A1 (en) 2024-03-27 2025-10-02 F. Hoffmann-La Roche Ag Interleukin-7 immunoconjugates
WO2025233304A1 (en) 2024-05-08 2025-11-13 F. Hoffmann-La Roche Ag Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2026033134A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1096187A (en) 1977-04-18 1981-02-24 Souhei Monden Ornament adapted to be fixed by permanent magnets
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
PT941329E (pt) 1996-11-29 2004-11-30 Applied Research Systems Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
CN101525384A (zh) 2000-06-29 2009-09-09 艾博特公司 双特异性抗体及其制备方法和用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP1476180A4 (en) 2001-08-13 2005-04-20 Univ Southern California MUTANTS OF INTERLEUKIN-2 WITH REDUCED TOXICITY
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
EP3020413A1 (en) 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
CN1703243B (zh) 2002-10-10 2011-05-04 默克专利有限公司 针对erb-b1受体的药物组合物
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060235201A1 (en) 2003-02-06 2006-10-19 Roman Kischel Enduring T cell response
WO2004078928A2 (en) 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
AU2003272065A1 (en) 2003-04-03 2004-10-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
CN104436190A (zh) 2005-06-08 2015-03-25 达纳-法伯癌症研究院公司 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US8623356B2 (en) 2005-11-29 2014-01-07 The University Of Sydney Demibodies: dimerization-activated therapeutic agents
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
CN101490085A (zh) 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US8231706B2 (en) 2006-09-20 2012-07-31 Mt-Biomethan Gmbh Method and device for separating methane and carbon dioxide from biogas
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
CA2673870A1 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009015917A2 (en) 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
WO2008156083A1 (ja) 2007-06-18 2008-12-24 Chugai Seiyaku Kabushiki Kaisha 抗体依存性細胞障害活性を模擬する抗体の結合活性測定法
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009024531A1 (en) 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
CA2703947C (en) 2007-10-26 2018-12-04 Governing Council Of The University Of Toronto Therapeutic and diagnostic methods using tim-3
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
ES2571879T3 (es) 2008-07-21 2016-05-27 Apogenix Ag Moléculas de una sola cadena de TNFSF
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
EP2370593B1 (en) 2008-11-28 2016-03-30 Emory University Methods for determining the efficacy of pd-1 antagonists
JP5569946B2 (ja) 2009-01-26 2014-08-13 国立大学法人 岡山大学 免疫抑制剤および自己免疫疾患の予防および治療剤
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
EP2396318A4 (en) 2009-02-11 2013-06-05 Life Technologies Corp COLORANTS WITH HIGH STOKES DERIVATION
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
MX2012002014A (es) 2009-08-17 2012-06-13 Roche Glycart Ag Inmunoconjugados dirigidos.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
CA3253628A1 (en) * 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
ES2682078T3 (es) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9266938B2 (en) * 2011-02-10 2016-02-23 Roche Glycart Ag Mutant interleukin-2 polypeptides
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
US9822179B2 (en) 2011-04-01 2017-11-21 Universitat Stuttgart Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
FR2977674B1 (fr) 2011-07-06 2015-08-14 Cisbio Bioassays Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
SG2014012298A (en) 2011-08-11 2014-06-27 Medarex Llc Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
FR2980271B1 (fr) 2011-09-16 2013-10-11 Cisbio Bioassays Procede de determination de la glycosylation d'un anticorps
HRP20201004T1 (hr) 2011-12-20 2020-10-16 Medimmune, Llc Modificirani polipeptidi za skelete bispecifičnog protutijela
CA2859268A1 (en) 2012-02-01 2013-08-08 F. Hoffmann-La Roche Ag Method for the detection of a binding partner of a multispecific binder
SI2814587T1 (en) 2012-02-15 2018-08-31 F. Hoffmann-La Roche Ag Affinity chromatography based on the Fc receptor
JP5585973B2 (ja) 2012-03-22 2014-09-10 三井造船株式会社 Ｆｒｅｔ計測装置及びｆｒｅｔ計測方法
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
MY174248A (en) 2012-04-30 2020-04-01 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CN104662045B (zh) * 2012-08-07 2019-04-05 罗切格利卡特公司 包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
WO2014055784A1 (en) 2012-10-03 2014-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
HRP20201113T1 (hr) 2013-03-15 2020-10-30 Glaxosmithkline Intellectual Property Development Limited Vežući proteini protiv lag-3
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
CN105612175B (zh) * 2013-08-08 2023-05-09 赛腾制药 基于IL-15和IL-15Rαsushi结构域的调节因子
SI3508502T1 (sl) 2013-09-20 2023-07-31 Bristol-Myers Squibb Company Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
US10794898B2 (en) 2014-01-17 2020-10-06 Regents Of The University Of Minnesota High-throughput, high-precision methods for detecting protein structural changes in living cells
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
KR20160106762A (ko) 2014-01-28 2016-09-12 브리스톨-마이어스 스큅 컴퍼니 혈액 악성종양을 치료하기 위한 항-lag-3 항체
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016030350A1 (en) * 2014-08-29 2016-03-03 F. Hoffmann-La Roche Ag Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
PL3215532T3 (pl) 2014-11-06 2020-03-31 F. Hoffmann-La Roche Ag Przeciwciała anty-TIM3 i sposoby ich zastosowania
DK3489256T3 (da) 2014-11-14 2021-05-25 Hoffmann La Roche Antigenbindende molekyler omfattende en TNF-familieligandtrimer
RU2753902C2 (ru) 2014-11-20 2021-08-24 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CA3175979A1 (en) 2014-12-22 2016-06-30 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3313883B1 (en) 2015-06-23 2023-12-06 Memorial Sloan Kettering Cancer Center Novel pd-1 immune modulating agents
CA2993177A1 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
RU2021133819A (ru) 2015-09-02 2021-12-10 Иммутеп С.A.С. Анти-lag-3 антитела
SMT202100506T1 (it) 2015-10-02 2021-11-12 Hoffmann La Roche Anticorpi bispecifici specifici per pd1 e tim3
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
KR102761077B1 (ko) 2015-10-02 2025-02-04 에프. 호프만-라 로슈 아게 높은 친화성을 갖는 항-인간 cd19 항체
EP3356821B1 (en) 2015-10-02 2019-10-23 H. Hoffnabb-La Roche Ag Cellular based fret assay for the determination of simultaneous binding
IL257858B (en) * 2015-10-02 2022-09-01 Hoffmann La Roche Anti-pd1 antibodies and methods of use
EP3913000A1 (en) 2015-10-02 2021-11-24 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
AU2016334623A1 (en) 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
MX377531B (es) 2015-11-03 2025-03-10 Hoffmann La Roche Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón.
US10858432B2 (en) 2015-12-02 2020-12-08 Stcube, Inc. Antibodies specific to glycosylated PD-1 and methods of use thereof
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
JP7572146B2 (ja) 2016-03-29 2024-10-23 エスティーキューブ アンド カンパニー，インコーポレイテッド グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
JP7285076B2 (ja) 2016-05-11 2023-06-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｔｎｆファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CN106519034B (zh) * 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
KR20190121816A (ko) 2017-04-03 2019-10-28 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
EP3606947B1 (en) 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CA3185303A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-a, tim-3, and lag-3
PL3606955T3 (pl) 2017-04-05 2025-02-24 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
BR112019021032A2 (pt) 2017-04-05 2020-05-05 Boehringer Ingelheim International Gmbh terapia combinada anticâncer
HUE060019T2 (hu) 2017-04-05 2023-01-28 Hoffmann La Roche Anti-LAG3 antitestek
JP2020516638A (ja) 2017-04-13 2020-06-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを処置する方法における使用のための、インターロイキン２イムノコンジュゲート、ｃｄ４０アゴニスト、および任意選択のｐｄ−１軸結合アンタゴニスト
MY205342A (en) 2017-11-01 2024-10-16 Hoffmann La Roche Bispecific 2+1 contorsbodies
CN111315781A (zh) 2017-11-01 2020-06-19 豪夫迈·罗氏有限公司 用靶向性ox40激动剂的组合疗法
SG11202112491WA (en) 2019-07-31 2021-12-30 Hoffmann La Roche Antibodies binding to gprc5d
CN115485028A (zh) 2020-04-15 2022-12-16 豪夫迈·罗氏有限公司 免疫缀合物
IL297880A (en) 2020-06-23 2023-01-01 Hoffmann La Roche Agonistic cd28 antigen binding molecules targeting her2
CN115916830A (zh) 2020-06-25 2023-04-04 豪夫迈·罗氏有限公司 抗cd3/抗cd28双特异性抗原结合分子
US11865082B2 (en) 2020-09-09 2024-01-09 Hoffmann-La Roche Inc. Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
MX2023007846A (es) 2021-01-06 2023-07-07 Hoffmann La Roche Tratamiento conjunto que usa un anticuerpo biespecifico contra pd1-lag3 y un anticuerpo biespecifico de linfocitos t cd20.
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
EP4304724A1 (en) 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
WO2022189377A1 (en) 2021-03-09 2022-09-15 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules

Also Published As

Publication number Publication date
RU2019134338A3 (es) 2021-05-05
JP7426825B2 (ja) 2024-02-02
HRP20221254T1 (hr) 2022-12-23
EP4201953A1 (en) 2023-06-28
KR20190121816A (ko) 2019-10-28
KR102461885B1 (ko) 2022-11-03
IL269395B1 (en) 2024-09-01
AR111400A1 (es) 2019-07-10
RU2761377C2 (ru) 2021-12-07
EP3606946A1 (en) 2020-02-12
IL269395A (en) 2019-11-28
MA49033B1 (fr) 2022-10-31
PL3606946T3 (pl) 2022-11-28
CN110392692A (zh) 2019-10-29
CN110392692B (zh) 2023-07-21
TWI800506B (zh) 2023-05-01
DK3606946T3 (da) 2022-10-24
CO2019009354A2 (es) 2019-09-09
US20250073308A1 (en) 2025-03-06
MX2023003397A (es) 2023-03-31
WO2018184964A1 (en) 2018-10-11
MX2019011770A (es) 2020-01-09
SG11201909205YA (en) 2019-11-28
RU2019134338A (ru) 2021-05-05
CL2019002346A1 (es) 2020-01-10
RS63663B1 (sr) 2022-11-30
PE20191494A1 (es) 2019-10-21
NZ756507A (en) 2025-06-27
LT3606946T (lt) 2022-10-25
TW201900220A (zh) 2019-01-01
BR112019017329A2 (pt) 2020-04-14
PT3606946T (pt) 2022-10-17
US20180326010A1 (en) 2018-11-15
CN117003887A (zh) 2023-11-07
HUE059885T2 (hu) 2023-01-28
MA49033A (fr) 2020-02-12
CA3053357A1 (en) 2018-10-11
MY201482A (en) 2024-02-26
US11413331B2 (en) 2022-08-16
JP2022062001A (ja) 2022-04-19
EP3606946B1 (en) 2022-08-24
KR20210124518A (ko) 2021-10-14
IL269395B2 (en) 2025-01-01
ES2928718T3 (es) 2022-11-22
ZA201905517B (en) 2021-05-26
US12023368B2 (en) 2024-07-02
JP2024045143A (ja) 2024-04-02
JP2020515275A (ja) 2020-05-28
PH12019502273A1 (en) 2020-12-07
AU2018247765B2 (en) 2023-11-23
US20230134606A1 (en) 2023-05-04
AU2018247765A1 (en) 2019-08-22
UA125700C2 (uk) 2022-05-18
AR126987A2 (es) 2023-12-06

Similar Documents

Publication Publication Date Title
CR20190426A (es) Inmunoconjugados
AR119338A1 (es) Inmunoconjugados que comprenden un polipéptido interleuquina-2 (il-2) mutante y un anticuerpo que se une a cd8
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
MX2022012541A (es) Inmunoconjugados.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
UY37456A (es) Inmunoglobulinas y sus usos
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
CO2018000882A2 (es) Constructos de anticuerpo para flt3 y cd3
BR112019012343A2 (pt) anticorpos il-11ra
CY1117842T1 (el) Πολυπεπτιδια μεταλλαγμενης il-2
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
BR112016021066A2 (pt) anticorpos humanizados com estabilidade aumentada
BR112019008345A2 (pt) anticorpos monoclonais ligados à isoforma transmembrana cd160
CL2024001066A1 (es) Nuevos inmunoconjugados de interleucina-7
MX377280B (es) Anticuerpo igf-ir y su uso para el diagnóstico del cáncer.
AR133025A2 (es) Constructos de anticuerpo para dll3 y cd3
AR105559A1 (es) Constructos de anticuerpo para cd70 y cd3
AR105558A1 (es) Constructos de anticuerpo para dll3 y cd3